retatrutide news today october 2025 Promises Big Weight Loss, but Safety Remains a Question Perceived benefits of treatment for
Description
patients interested in trial eligibility should speak to their GP or check ClinicalTrials.gov
Efficacy: Clinical studies show patients losing 15-22% of their body weight, surpassing the results typically seen with GLP-1 agonists
Additional evaluation may include assessment for HIV or other immunocompromising conditions
Eli Lillys dulaglutide was approved in September 2014 under the name Trulicity as a Type 2 diabetes treatment
Hasan M, Schwartz S, McKenna V, Ing R
Chandler says
